Stimulating a multi-faceted immune response against cancer’s Achilles heel: the tumor endothelium

Batu Biologics has developed a novel approach to fighting cancer through vaccines and immune stimulation. Its core product ValloVax™ is a cellular anti-angiogenic cancer vaccine designed to stimulate an immune response against the tumor endothelium for the initial condition of lung cancer. ValloVax targets multiple proteins found on the tumor-associated blood vessels and seeks to target and prevent tumor angiogenesis.

Why is the Tumor Endothelium the target of Vallovax™?

  1. No mutation means that the blood vessels around the tumor do not develop drug resistance.
  2. Without angiogenesis, or the formation of new blood vessels, the tumor cannot exceed 1 to 2 mm in diameter.
  3. The tumor endothelium is in direct contact with the body’s immune system, addressing the issue of drug delivery to hypoxic areas of the tumor.

The diagram above was published in the journal, Oncotarget, and describes the mechanism of action of the ValloVax induced immune response

Current angiogenesis inhibitors, such as Avastin, target only one of the key pathways of angiogenesis (VEGF). In contrast, ValloVax™ stimulates the immune system to attack multiple pathways necessary for angiogenesis, thus having the potential for superior efficacy and specificity in comparison with existing drugs. ValloVax™ is differentiated from current anti-angiogenic therapies because it stimulates the direct immune system killing of the tumor endothelium while existing tyrosine-kinase inhibitors merely block the VEGF pathway – slowing the angiogenic process at best.

Batu Biologics has developed the vaccine and proprietary extraction system and has filed several patents in the field of immunothereputic cancer vaccines. The company is in the process of filing its 28th provisional patent in the field of cancer immunotherapy. Batu’s strategy is focused on preparing ValloVax™ to enter Phase I clinical trials.

Batu Biologics is targeting non small cell lung cancer (NSCLC) as the first treatment indication for ValloVax™, with expanded indications to follow.

Currently, Batu Biologics is seeking to complete the development and characterization of ValloVax™, completing the pre-clinical testing and preparing and filing an Investigational New Drug (IND) application in anticipation of a Phase I clinical trial for advanced lung cancer. Batu Biologics will continue to optimize the value of its technologies through IP expansion, license opportunities, and co-development of secondary treatment indications.

With the recent successes of immunotherapy in a variety of tumors, Batu Biologics believes there is an increasing unmet need for non-toxic immune modulators that can augment efficacy of existing therapeutics. Our Team is motivated to bring novel therapeutics to the forefront of medical research that use the power of the body’s own immune system to extend life expectancy.